Trial Profile

A Phase 1b, Dose Escalation, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacological Effect of a Single Intravenous Infusion of Belantamab in Participants With Autoimmune Disease

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 10 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Belantamab (Primary)
Indications Antiphospholipid syndrome; Autoimmune disorders; Rheumatoid arthritis; Systemic lupus erythematosus
Focus Adverse reactions
Sponsors GSK

03 Jun 2025 Status changed from recruiting to withdrawn prior to enrolment.
20 Apr 2025 Planned End Date changed from 27 Nov 2025 to 21 Sep 2026.
11 Mar 2025 Trial amended with autoimmune diseases including rheumatoid arthritis and antiphospholipid syndrome.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com